Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer
Not Applicable
Terminated
- Conditions
- Metastatic Pancreatic Cancer
- Registration Number
- NCT02921646
- Lead Sponsor
- Center Eugene Marquis
- Brief Summary
The purpose of this study is to determine whether evolution of resting energetic expenditure is a predictive marker of tumoral response for patients suffering from metastatic pancreatic cancer and treated with 1st line of chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Pancreatic metastatic cancer
- Patient older than 18 years
- Initiation of a first line of chemotherapy by Folfirinox, or Gemcitabine or in combination with Nab-Paclitaxel.
- At least one measurable target lesion
- Patient signed consent for Energie-Pancreas study participation
Exclusion Criteria
- Other concomitant cancer
- Major general status alteration ( Performance status = 3 or 4 at inclusion)
- Concomitant diseases explaining an altered general status or having an impact on energetic expenditure (i.e.chronic or severe infection, severe cardiac insufficiency, severe respiratory insufficiency, chronic inflammatory disease, recent surgery (< 1 month), ongoing Healing, hyperthyroidism.
- Smoker
- Patient deprived of his liberty, under guardianship, curator.
- Pregnant patient or breastfeeding
- Claustrophobic patient
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Resting energetic expenditure measurement by indirect calorimetry 4 months Unit measure : calorie per day
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre Eugène Marquis
🇫🇷Rennes, France
Centre Eugène Marquis🇫🇷Rennes, France